Functional properties of a novel mutant of staphylokinase with platelet-targeted fibrinolysis and antiplatelet aggregation activities

Hongshan Chen, Wei Mo, Yanling Zhang, Huabo Su, Janying Ma, Ruiming Yao, Shaoheng Zhang, Junbo Ge, Houyan Song

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The present study was performed to characterize the functional properties of RGD-SAK, a novel mutant of staphylokinase (SAK). Biochemical analysis indicated that RGD-SAK maintained the similar structure and the fibrinolytic function of SAK. Measurement of platelet binding activity in vitro demonstrated that RGD-SAK had a much higher affinity with platelets than SAK. In vitro platelet-rich clot lysis assay demonstrated that the engineered mutant outperformed the non-manipulated SAK. The time required for 50% platelet-rich clot lysis was reduced significantly across different concentrations of RGD-SAK comparing with SAK. Meanwhile, RGD-SAK was found to inhibit ADP-induced platelet aggregation in a concentration-dependent manner while SAK had negligible effect on platelet aggregation. In concordance, further study in a porcine coronary balloon injury model demonstrated the efficacy of RGD-SAK for the lysis of platelet-rich coronary blood clots and for the prevention of reocclusion after thrombolysis. These results suggested that RGD-SAK may serve as a potential thrombolytic agent with platelet-targeted fibrinolysis and antiplatelet aggregation activities.

Original languageEnglish (US)
Pages (from-to)137-144
Number of pages8
JournalEuropean Journal of Pharmacology
Volume566
Issue number1-3
DOIs
StatePublished - Jul 2 2007
Externally publishedYes

Fingerprint

Fibrinolysis
Blood Platelets
Platelet Aggregation
Staphylococcus aureus auR protein
Fibrinolytic Agents
Adenosine Diphosphate
Thrombosis
Swine

Keywords

  • Antiplatelet activity
  • Platelet-targeted fibrinolysis
  • RGD motif
  • Staphylokinase

ASJC Scopus subject areas

  • Pharmacology

Cite this

Functional properties of a novel mutant of staphylokinase with platelet-targeted fibrinolysis and antiplatelet aggregation activities. / Chen, Hongshan; Mo, Wei; Zhang, Yanling; Su, Huabo; Ma, Janying; Yao, Ruiming; Zhang, Shaoheng; Ge, Junbo; Song, Houyan.

In: European Journal of Pharmacology, Vol. 566, No. 1-3, 02.07.2007, p. 137-144.

Research output: Contribution to journalArticle

Chen, Hongshan ; Mo, Wei ; Zhang, Yanling ; Su, Huabo ; Ma, Janying ; Yao, Ruiming ; Zhang, Shaoheng ; Ge, Junbo ; Song, Houyan. / Functional properties of a novel mutant of staphylokinase with platelet-targeted fibrinolysis and antiplatelet aggregation activities. In: European Journal of Pharmacology. 2007 ; Vol. 566, No. 1-3. pp. 137-144.
@article{b312707ad9ed483eb70a72b5590f4ccf,
title = "Functional properties of a novel mutant of staphylokinase with platelet-targeted fibrinolysis and antiplatelet aggregation activities",
abstract = "The present study was performed to characterize the functional properties of RGD-SAK, a novel mutant of staphylokinase (SAK). Biochemical analysis indicated that RGD-SAK maintained the similar structure and the fibrinolytic function of SAK. Measurement of platelet binding activity in vitro demonstrated that RGD-SAK had a much higher affinity with platelets than SAK. In vitro platelet-rich clot lysis assay demonstrated that the engineered mutant outperformed the non-manipulated SAK. The time required for 50{\%} platelet-rich clot lysis was reduced significantly across different concentrations of RGD-SAK comparing with SAK. Meanwhile, RGD-SAK was found to inhibit ADP-induced platelet aggregation in a concentration-dependent manner while SAK had negligible effect on platelet aggregation. In concordance, further study in a porcine coronary balloon injury model demonstrated the efficacy of RGD-SAK for the lysis of platelet-rich coronary blood clots and for the prevention of reocclusion after thrombolysis. These results suggested that RGD-SAK may serve as a potential thrombolytic agent with platelet-targeted fibrinolysis and antiplatelet aggregation activities.",
keywords = "Antiplatelet activity, Platelet-targeted fibrinolysis, RGD motif, Staphylokinase",
author = "Hongshan Chen and Wei Mo and Yanling Zhang and Huabo Su and Janying Ma and Ruiming Yao and Shaoheng Zhang and Junbo Ge and Houyan Song",
year = "2007",
month = "7",
day = "2",
doi = "10.1016/j.ejphar.2007.03.010",
language = "English (US)",
volume = "566",
pages = "137--144",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Functional properties of a novel mutant of staphylokinase with platelet-targeted fibrinolysis and antiplatelet aggregation activities

AU - Chen, Hongshan

AU - Mo, Wei

AU - Zhang, Yanling

AU - Su, Huabo

AU - Ma, Janying

AU - Yao, Ruiming

AU - Zhang, Shaoheng

AU - Ge, Junbo

AU - Song, Houyan

PY - 2007/7/2

Y1 - 2007/7/2

N2 - The present study was performed to characterize the functional properties of RGD-SAK, a novel mutant of staphylokinase (SAK). Biochemical analysis indicated that RGD-SAK maintained the similar structure and the fibrinolytic function of SAK. Measurement of platelet binding activity in vitro demonstrated that RGD-SAK had a much higher affinity with platelets than SAK. In vitro platelet-rich clot lysis assay demonstrated that the engineered mutant outperformed the non-manipulated SAK. The time required for 50% platelet-rich clot lysis was reduced significantly across different concentrations of RGD-SAK comparing with SAK. Meanwhile, RGD-SAK was found to inhibit ADP-induced platelet aggregation in a concentration-dependent manner while SAK had negligible effect on platelet aggregation. In concordance, further study in a porcine coronary balloon injury model demonstrated the efficacy of RGD-SAK for the lysis of platelet-rich coronary blood clots and for the prevention of reocclusion after thrombolysis. These results suggested that RGD-SAK may serve as a potential thrombolytic agent with platelet-targeted fibrinolysis and antiplatelet aggregation activities.

AB - The present study was performed to characterize the functional properties of RGD-SAK, a novel mutant of staphylokinase (SAK). Biochemical analysis indicated that RGD-SAK maintained the similar structure and the fibrinolytic function of SAK. Measurement of platelet binding activity in vitro demonstrated that RGD-SAK had a much higher affinity with platelets than SAK. In vitro platelet-rich clot lysis assay demonstrated that the engineered mutant outperformed the non-manipulated SAK. The time required for 50% platelet-rich clot lysis was reduced significantly across different concentrations of RGD-SAK comparing with SAK. Meanwhile, RGD-SAK was found to inhibit ADP-induced platelet aggregation in a concentration-dependent manner while SAK had negligible effect on platelet aggregation. In concordance, further study in a porcine coronary balloon injury model demonstrated the efficacy of RGD-SAK for the lysis of platelet-rich coronary blood clots and for the prevention of reocclusion after thrombolysis. These results suggested that RGD-SAK may serve as a potential thrombolytic agent with platelet-targeted fibrinolysis and antiplatelet aggregation activities.

KW - Antiplatelet activity

KW - Platelet-targeted fibrinolysis

KW - RGD motif

KW - Staphylokinase

UR - http://www.scopus.com/inward/record.url?scp=34249082431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249082431&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2007.03.010

DO - 10.1016/j.ejphar.2007.03.010

M3 - Article

VL - 566

SP - 137

EP - 144

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -